A tumor-targeted heptamethine cyanine dye induces suppression of progesterone receptor activity to treat hormone receptor-positive breast cancer.

ABSTRACT: Background: A primary treatment of hormone receptor-positive breast cancer is the pharmacological inhibition of hormone receptors by blocking the effects of estrogen and/or progesterone. Methods: In MCF-7 xenograft tumors known as estrogen-sensitive breast cancer, a hydrophilic near-infrared (NIR) heptamethine cyanine dye (named CA800-PR) induced Golgi fragmentation and suppressed only progesterone receptor protein expression, regardless of estrogen receptors. Results: In this study, CA800-PR was newly developed for the treatment of hormone receptor-positive breast cancer unlike conventional drugs such as tamoxifen and aromatase inhibitors. Since the intracellular stress induced by CA800-PR led to the production of pro-inflammatory cytokines, we confirmed a significant

SUBMITTER: Park Y 

PROVIDER: S-EPMC12775649 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature